A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas

A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma

(2018) Ruichao Chai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas

(2018) Rui-Chao Chai et al.   CNS Neuroscience & Therapeutics

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients

(2017) Guoqiang Yuan et al.   JOURNAL OF NEURO-ONCOLOGY

CGCG clinical practice guidelines for the management of adult diffuse gliomas

(2016) Tao Jiang et al.   CANCER LETTERS

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR

(2016) Daniel Xia et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors

(2016) Pierre Bady et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma

(2016) Giovanni Brigliadori et al.   JOURNAL OF NEURO-ONCOLOGY

Bioinformatic profiling identifies an immune-related risk signature for glioblastoma

(2016) Wen Cheng et al.   NEUROLOGY

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis

(2016) Hailong Zhao et al.   World Journal of Surgical Oncology

Digital PCR quantification ofMGMTmethylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer

(2015) L. Barault et al.   ANNALS OF ONCOLOGY

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

(2015) Michal Bienkowski et al.   CLINICAL NEUROPATHOLOGY

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients

(2015) Pilar Mur et al.   JOURNAL OF NEURO-ONCOLOGY

TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide

(2015) Robert W. Rapkins et al.   NEURO-ONCOLOGY

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

(2014) Véronique Quillien et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

(2013) Sandra H E Boots-Sprenger et al.   MODERN PATHOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations

(2013) João Ramalho-Carvalho et al.   PLoS One

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy w

(2012) Emmanuèle Lechapt-Zalcman et al.   CANCER

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

(2012) W. Zhang et al.   NEURO-ONCOLOGY

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

(2012) Arne Christians et al.   PLoS One

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

(2011) Shani Mulholland et al.   INTERNATIONAL JOURNAL OF CANCER

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

(2008) Ilse Vlassenbroeck et al.   JOURNAL OF MOLECULAR DIAGNOSTICS